New data from MycoMeditations, a leading name in psilocybin-assisted retreats based in Jamaica, reveals encouraging therapeutic outcomes for individuals suffering from post-traumatic stress disorder (PTSD).
The findings, based on the PCL-5 scale, showcase significant reductions in PTSD symptoms post-treatment.
The protocol consisted of three spaced-out dosing sessions and guided group integration.
Participants consumed the dried Psilocybe cubensis mushroom, encapsulated into 0.5g doses, with the amount increasing progressively over three sessions.
Notably, participants who began the retreat with a PCL-5 score indicating pronounced PTSD symptoms (averaging at 43.04) reported a significant decline to an average of 17.90 only one month post-retreat.
Such a change surpasses the threshold for clinical significance. Moreover, the decline in symptoms sustained through to the 12-month mark post-retreat.
In comparison to the MAPS PBC Phase 3 trial outcomes, MycoMeditations’ results displayed quicker therapeutic benefits.
The MAPS data, based on the CAPS-5 scale, showed a 55.5% symptom reduction over 18 weeks.
In contrast, MycoMeditations observed a 52.7% reduction just three months post-retreat, which largely maintained six months later with a 48.8% decrease.
While these findings are not part of an official academic study or clinical trial, the results point to the immense potential of psilocybin, particularly in group therapeutic settings, as a viable PTSD treatment.
However, it’s essential to acknowledge the importance of continued therapeutic support post-retreat for optimal long-term outcomes.
MycoMeditations has been at the forefront of psilocybin therapy and wellness tourism since 2014, offering over 6,000 doses of therapeutic psilocybin to over 2,000 clients.
The organisation hopes this data will drive further exploration into the therapeutic potential of psychedelics in mental health.